NSCLC组织中β-微管蛋白Ⅲ、stathmin蛋白表达变化及意义  

Change of stathmin andβ-tubulinⅢ expression in NSCLC and its influence to taxol sensitivity

作　　者：杜亚明[1] 王宝华[2] 王天一[1] 哈敏文[1] 王中彬[1] 

机构地区：[1]辽宁医学院第一附属医院,辽宁锦州121001 [2]华北煤炭医学院

出　　处：《山东医药》2010年第38期18-20,共3页Shandong Medical Journal

基　　金：辽宁省科技计划资助项目(2007225005-13)

摘　　要：目的观察非小细胞肺癌（NSCLC）组织中的stathmin、β-tubulinⅢ,并探讨其与紫杉醇化疗疗效的的关系。方法采用免疫组化SP法检测123例NSCLC患者肿瘤组织（观察组）和15例炎性假瘤患者瘤组织（对照组）中的stathmin、-βtubulinⅢ,并对其中行根治术后用紫杉醇类药物行辅助化疗的32例NSCLC患者的疗效进行分析。结果 NSCLC组织中stathmin、-βtubulinⅢ蛋白表达阳性率分别为52.8%、62.6%,显著高于良性对照组的6.7%、13.3%（P均〈0.05）。stathmin蛋白均在低分化和有淋巴转移的肿瘤中表达明显升高（P均〈0.05）;-βtubu linⅢ蛋白在低分化和Ⅲ~Ⅳ期肿瘤中表达明显升高（P均〈0.05）。32例术后用含紫杉醇化疗方案化疗的患者中,stath-min、-βtubulinⅢ蛋白表达全阳性者的生存率较全阴性者低（P〈0.05）。结论 NSCLC患者肿瘤组织中stathmin、β-tubulinⅢ蛋白均明显升高。二者表达均阳性预示着肿瘤的恶性程度较高,对紫杉醇类化疗药物的敏感性较差,术后预后较差。Objective To observe the change of stathmin and β-tubulinⅢ expression in NSCLC and its influence to taxol sensitivity.Methods Expression of stathmin and β-tubulinⅢ in 32 patients with NSCLC who received radical surgery paclitaxel-based chemotherapy were determined by immunohistochemical method.It is that the correlation of their expression analized with prognosis and prediction value in chemotherapy.Results The positive rates of stathmin,β-tubulinⅢ were 52.8% and 62.6%,significant more than inflammatory pseudotumor（P〈0.05）.The positive rates of stathmin have significant difference in poorly differentiated group and lymphatic metastasis group（P〈0.05）;The positive rates of β-tubulin Ⅲ have significant difference in poorly differentiated group and Ⅲ~Ⅳ state group（P〈0.05）.The expression of stathmin,β-tubulinⅢ in the patients who had postoperative chemotherapy were subdivided into two group（all positive,all negative）,there showd significant survival difference between all positive and all negative.Conclusion The expression of stathmin and β-tubulin Ⅲ increase in NSCLC tissues.It suggests that the tumor is malignant taxol-unsensitive and poor prognosis.

关 键 词：肺肿瘤 非小细胞肺癌 STATHMIN蛋白 -βtubulinⅢ蛋白 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]